Istanbul, March 2025 – Turkiye-based Centurion İlaç Sanayi ve Ticaret A.Ş. has signed a strategic collaboration agreement with UK-based Accord Healthcare Ltd. to expand access to innovative biotechnology treatments in Turkiye. This partnership marks an important milestone in advancing patient access to high-quality, cutting-edge therapeutic solutions.
Through this agreement, Centurion and Accord will leverage their expertise in biotechnology and oncology to bring advanced treatments to patients and healthcare professionals in Turkiye. This collaboration reinforces the commitment of both companies to innovation, scientific advancement, and improving treatment outcomes.
Dr. Akın Aksekili, General Manager of Centurion İlaç Sanayi ve Ticaret A.Ş., stated:
"This agreement marks a significant milestone for Centurion. Ensuring patient access to this critical treatment and providing physicians with a vital therapeutic option is a great responsibility for us. We are committed to strengthening our presence in the field of oncology and aim to provide more patients with access to advanced treatments."
Paul Tredwell, Executive Vice-President, EMENA, Accord Healthcare, added:“At Accord, we are committed to transforming the lives of patients. Our licensing agreement with Centurion enables us to provide a new and essential treatment option. This partnership underscores our dedication to developing specialty medicines that truly impact patients' lives across Europe and beyond.”
The partnership highlights a shared vision of advancing healthcare through biotechnology-driven solutions, scientific research, and global expertise. By combining their strengths, Centurion and Accord are set to play a crucial role in enhancing access to next-generation treatments in Turkiye.
